Should immune checkpoint inhibitor be held for palliative RT to bladder in patient with metastatic urothelial carcinoma who has stable systemic disease on immunotherapy?

Topics: Radiation Oncology • Genitourinary Cancers • Bladder Cancer • Medical Oncology

What is the potential risk of immunotherapy toxicity in combining palliative RT in a patient already on immunotherapy?

Answer from: Medical Oncologist at Academic Institution

I assume the scenario applies to patients with good systemic disease control on immune checkpoint inhibitor (ICI) but with symptomatic primary tumor of the bladder, e.g. hematuria, pain, and obstruction. It is helpful to have a good discussion between Med Onc & Rad Onc regarding the optimal timi...

Comments

Medical Oncologist at University of Michigan Medical School
We have conducted and presented our study of nivo ...

Answer from: Medical Oncologist at Community Practice

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy (52 Gy in 20 fractions over 4 weeks, i.e., 1 fraction = 2.6 Gy) was reported to be a safe and efficacious, bladder-sparing investigational regimen for patients with muscle-invasive bladder cancer (MIBC) in a p...

Related Questions